DelveInsight’s, “IgA Nephropathy Pipeline Insight, 2023,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in IgA Nephropathy pipeline landscape. It covers the IgA Nephropathy pipeline drug profiles, including IgA Nephropathy clinical trial and nonclinical stage products. It also covers the IgA Nephropathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the IgA Nephropathy Pipeline Report
Discover the latest developmental activities in the IgA nephropathy treatment landscape @ IgA Nephropathy Pipeline Outlook
IgA Nephropathy Overview
IgA nephropathy, also known as Berger’s disease, is a kidney disease that occurs when IgA deposits build up in the kidneys, causing inflammation that damages kidney tissues. IgA is an antibody—a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. It is not known what causes IgA deposits in the glomeruli. In more than 10% of affected families, it is inherited. Each person may have a different set of signs and symptoms from IgAN. The Most common symptoms are: Hematuria and Proteinuria, Swelling in ankles and High Blood pressure. Urine test, Blood test, Glomerular Filtration rate, Kidney Biopsy are some of the procedures that helps in the diagnosis of IgA Nephropathy. There is no cure for IgA nephropathy, but treatments can help to prevent more damage to your kidneys.
Recent Developmental Activities in the IgA Nephropathy Treatment Landscape
Learn more about the IgA nephropathy emerging therapies @ IgA Nephropathy Ongoing Clinical Trials Analysis
IgA Nephropathy Emerging Drugs
Atrasentan: Chinook Therapeutics
Atrasentan is a potent and selective, small molecule inhibitor of the endothelin A receptor for the potential treatment of IgA Nephropathy (IgAN) and other proteinuric glomerular diseases. Chinook Therapeutics has initiated a phase III trial (ALIGN) of Atrasentan in early 2021 in patients with IgAN at high risk of kidney function decline.
Sparsentan: Travere Therapeutics
Sparsentan is a novel small-molecule candidate in Phase III development for the treatment of IgA nephropathy (IgAN). IgAN, also called Berger’s disease, is a type of glomerulonephritis. Sparsentan is a single molecule designed to selectively block the receptors of two pathways which are associated with kidney disease progression. The receptors are endothelin 1A and angiotensin II type 1. In March 2022, Travere Therapeutics, Inc. announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN).
IgA Nephropathy Therapeutics Assessment
There are approx. 30+ key companies which are developing the therapies for IgA Nephropathy. The companies which have their IgA Nephropathy drug candidates in the most advanced stage, i.e. Preregistration include, Travere Therapeutics.
Explore more about the IgA Nephropathy Key Companies and Drugs of the report @ IgA Nephropathy Treatment Landscape
Scope of the IgA Nephropathy Pipeline Report
Table of Content
Dive deep into rich insights for IgA nephropathy Emerging Drugs Profile, visit @ IgA Nephropathy Companies and Drugs
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/